- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01169493
Pacing Affects Cardiovascular Endpoints in Patients With Right Bundle-Branch Block (The PACE-RBBB Trial) (PACE-RBBB)
1. august 2016 oppdatert av: Duke University
Heart failure (HF) affects 5 million Americans and is responsible for more health-care expenditure than any other medical diagnosis.
Approximately half of all HF patients have electrocardiographic prolongation of the QRS interval and ventricular dyssynchrony, a perturbation of the normal pattern of ventricular contraction that reduces the efficiency of ventricular work.
Ventricular dyssynchrony is directly responsible for worsening HF symptomatology in this subset of patients.
Resynchronization of ventricular contraction is usually achieved through simultaneous pacing of the left and right ventricles using a biventricular (BiV) pacemaker or implantable cardioverter-defibrillator.
Clinical trial evidence supporting the use of BiV pacing in patients with prolonged QRS duration was obtained almost exclusively in patients with a left bundle-branch block (LBBB) electrocardiographic pattern.
Recent evidence suggests that resynchronization of ventricular contraction in patients with LBBB can be obtained by univentricular left ventricular pacing with equal or superior clinical benefits compared to BiV pacing.
Animal studies suggest that ventricular resynchronization can be obtained in subjects with right bundle-branch block (RBBB) through univentricular right ventricular pacing.
No clinical trial evidence exists to support the use of BiV pacing in patients with RBBB.
Thousands of patients with symptomatic HF and RBBB currently have univentricular ICDs in place for the prevention of sudden cardiac death.
Most of these devices are currently programmed to avoid RV pacing.
We aim to determine if ventricular resynchronization delivered through univentricular RV pacing improves symptoms in patients with RBBB and moderate to severe HF who have previously undergone BiV ICD implantation for symptomatic heart failure.
We further aim to determine if ventricular resynchronization improves myocardial performance and ventricular geometry as detected by echocardiographic measures and quality of life for patients with HF and RBBB.
We hypothesize that RV univentricular pacing delivered with an atrio-ventricular interval that maximizes ventricular synchrony is equivalent to BiV pacing for improvement in cardiac performance, HF symptoms, and positive ventricular remodeling in patients with HF and RBBB.
Studieoversikt
Status
Avsluttet
Forhold
Intervensjon / Behandling
Studietype
Intervensjonell
Registrering (Faktiske)
16
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
North Carolina
-
Durham, North Carolina, Forente stater, 27710
- Duke University Medical Center
-
Durham, North Carolina, Forente stater, 27710
- Durham VA Medical Center
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år og eldre (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Cardiomyopathy of either idiopathic or ischemic etiology
- NYHA class III, or IV symptoms
- Sinus rhythm
- QRS complex duration > 130 msec in ≥ 2 surface ECG leads with RBBB
- PR interval > 150 msec and < 240 msec
- Prior implantation of dual chamber BiV ICD with apical RV lead location
Exclusion Criteria:
- Myocardial infarction, major surgical procedure, or acute cardiac failure crisis requiring inotropes within 6 months of entry into the study
- Atrial fibrillation or flutter lasting >12 hours within the last 6 months
- Sick sinus syndrome, complete heart block, or other arrhythmias requiring pacemaker support
- Pregnancy
- Any other known condition other than heart failure that could limit exercise time or survival to < 6 months
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Crossover-oppdrag
- Masking: Trippel
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: VVI-40 to RV DDD-40 to Bi-V DDD-40
Period 1: Participants assigned to VVI-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to RV DDD-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to Bi-V DDD-40
|
Pacing mode set to VVI-40, RV only pacing
ICD programmed to DDD-40, RV only pacing with aan AV interval producing QRS fusion on surface EKG.
ICD programmed to BiV pacing at a lower rate of 40
|
|
Eksperimentell: VVI-40 to Bi-V DDD-40 to RV DDD-40
Period 1: Participants assigned to VVI-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to Bi-V DDD-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to RV DDD-40
|
Pacing mode set to VVI-40, RV only pacing
ICD programmed to DDD-40, RV only pacing with aan AV interval producing QRS fusion on surface EKG.
ICD programmed to BiV pacing at a lower rate of 40
|
|
Eksperimentell: Bi-V DDD-40 to VVI-40 to RV DDD-40
Period 1: Participants assigned to Bi-V DDD-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to VVI-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to RV DDD-40
|
Pacing mode set to VVI-40, RV only pacing
ICD programmed to DDD-40, RV only pacing with aan AV interval producing QRS fusion on surface EKG.
ICD programmed to BiV pacing at a lower rate of 40
|
|
Eksperimentell: Bi-V DDD-40 to RV DDD-40 to VVI-40
Period 1: Participants assigned to Bi-V DDD-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to RV DDD-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to VVI-40
|
Pacing mode set to VVI-40, RV only pacing
ICD programmed to DDD-40, RV only pacing with aan AV interval producing QRS fusion on surface EKG.
ICD programmed to BiV pacing at a lower rate of 40
|
|
Eksperimentell: RV DDD-40 to VVI-40 to Bi-V DDD-40
Period 1: Participants assigned to RV DDD-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to VVI-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to Bi-V DDD-40
|
Pacing mode set to VVI-40, RV only pacing
ICD programmed to DDD-40, RV only pacing with aan AV interval producing QRS fusion on surface EKG.
ICD programmed to BiV pacing at a lower rate of 40
|
|
Eksperimentell: RV DDD-40 to Bi-V DDD-40 to VVI-40
Period 1: Participants assigned to RV DDD-40 Participants will then Crossover to Period 2. Period 2: Participants assigned to Bi-V DDD-40 Participants will then Crossover to Period 3. Period 3: Participants assigned to VVI-40
|
Pacing mode set to VVI-40, RV only pacing
ICD programmed to DDD-40, RV only pacing with aan AV interval producing QRS fusion on surface EKG.
ICD programmed to BiV pacing at a lower rate of 40
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
The Primary Endpoint of the Trial Will be a Comparison of the Proportion of Patients in Each of the Three Treatment Groups Who Demonstrate Positive LV Remodeling, Defined as a Decrease in LV End Systolic Diameter of >5mm.
Tidsramme: 6 months
|
6 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Venstre ventrikkel ejeksjonsfraksjon (LVEF)
Tidsramme: 6 måneder
|
6 måneder
|
|
|
Secondary Echocardiographic Endpoints
Tidsramme: 6 months
|
Comparisons of the derived velocity-time integral calculated on the aortic continuous wave Doppler-spectrogram, RV end-diastolic size, RV EF, mitral and tricuspid regurgitation severity, and estimated RV systolic pressure.
|
6 months
|
|
Arrhythmic Events
Tidsramme: 6 months
|
To determine if pacing mode impacts the frequency of ventricular arrhythmias, the incidence of ventricular tachyarrhythmia episodes on device interrogation will be compared between treatment group assignments.
An episode will be considered ventricular arrhythmia if it lasts longer than 30 seconds or requires anti-tachycardia pacing or high voltage device therapy for termination.
|
6 months
|
|
Minnesota Quality of Life Questionnaire
Tidsramme: 6 months
|
This is a standardized method for assessing quality of life in patients with heart failure.
It asks 21 questions and measures the impact HF has on a subject's life.
Each question is rated 0-5.
The total score for the 21 items can range from 0 to 105.
Higher scores indicate more burden of disease on quality of life.
|
6 months
|
|
6-minute Walk Distance
Tidsramme: 6 months
|
6-minute walk distance was the distance that a participant could walk in 6 minutes.
|
6 months
|
|
NYHA Function Class
Tidsramme: 6 months
|
The New York Heart Association (NYHA) Functional Classification places patients in one of four categories based on how much they are limited during physical activity.
Class I means there is no limitation of physical activity and Class IV means a person is unable to carry on any physical activity without discomfort/symptoms of heart failure at rest.
|
6 months
|
|
Left Ventricular End-diastolic Size
Tidsramme: 6 months
|
6 months
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Brett D Atwater, MD, Duke University
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. januar 2011
Primær fullføring (Faktiske)
1. august 2014
Studiet fullført (Faktiske)
1. august 2014
Datoer for studieregistrering
Først innsendt
22. juli 2010
Først innsendt som oppfylte QC-kriteriene
22. juli 2010
Først lagt ut (Anslag)
26. juli 2010
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
23. september 2016
Siste oppdatering sendt inn som oppfylte QC-kriteriene
1. august 2016
Sist bekreftet
1. august 2016
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- Pro00025144
- 10CRP3630033 (Annet stipend/finansieringsnummer: American Heart Association)
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .